Recent developments include mixed financial results for 2024, clinical momentum updates, and leadership changes due to strategic adjustments.

• Zhongchao Inc. reported mixed financial results for 2024, highlighting ongoing operational challenges and financial performance considerations [N2].
• The company experienced clinical momentum and recent updates that contributed to after-hours rally activity in October 2025 [N1].
• Investor concerns about the company's returns on capital have been expressed in public commentary, reflecting scrutiny of financial efficiency [N3].
• Three officers resigned in March 2026 due to business strategy adjustments; the resignations were not related to disagreements with the company [S2].

Zhongchao Inc. benefits from a diversified healthcare platform that combines online education, professional training, patient management, and pharmaceutical services, addressing significant needs in China's healthcare sector. The MDMOOC platform's recognized brand and expanding course offerings across multiple medical specialties support user engagement and potential market leadership. The company's strong liquidity position provides financial flexibility. Recent clinical momentum and updates have generated positive market interest, indicating potential for operational progress. Strategic adjustments and leadership changes may enable the company to refine its focus and improve execution.

The company reported a net loss of $6.3 million for the fiscal year ended 2025, reflecting ongoing profitability challenges. Investor concerns about returns on capital have been noted in public commentary. The complex VIE structure and offshore holding company status introduce regulatory and operational risks. Recent resignations of key officers may indicate internal challenges or strategic uncertainty. The cessation of Xinjiang Pharmaceutical operations suggests difficulties in certain business segments. Competitive pressures in the Chinese healthcare education and pharmaceutical markets may limit growth and margin expansion.

Zhongchao Inc.'s moat is based on its established MDMOOC brand, recognized as a leading online medical education platform in China, supported by a comprehensive content library, interactive community features, and cooperation with medical associations and international education providers. The integration of online and onsite training services, along with patient management systems and patient-aid projects, creates a differentiated service offering that addresses multiple needs along the patient and healthcare professional journey. The company's contractual arrangements enable consolidation of PRC operating entities despite regulatory restrictions on foreign ownership, providing operational control. However, the moat is challenged by competitive pressures in the Chinese healthcare education market and regulatory complexities inherent in the VIE structure.

• Regulatory and Structural Risks: The company operates through a VIE structure consolidating PRC entities, which may face regulatory scrutiny or changes affecting operational control and financial consolidation.
• Profitability Challenges: The company reported net losses and negative earnings per share, indicating ongoing challenges in achieving profitability.
• Leadership Changes: Recent resignations of key officers due to business strategy adjustments may impact execution and operational continuity.
• Market Competition: The healthcare education and pharmaceutical services markets in China are competitive, which may pressure market share and margins.

• Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands with no substantive operations of its own, consolidating financial results of PRC operating entities through contractual arrangements [S1].
• The PRC operating entities operate under Zhongchao Medical Technology (Shanghai) Corp. and its subsidiaries, providing healthcare information, professional training, education services to healthcare professionals, patient management services in oncology and rare diseases, internet healthcare services, and pharmaceutical sales in China [S1].
• The company operates the MDMOOC brand, a leading online platform in China for medical education and training, offering courses via mobile app, WeChat subscription, and website, targeting healthcare professionals [S1].
• The PRC operating entities also provide patient management services through IT systems and WeChat mini programs, serving pharmaceutical enterprises and not-for-profit customers [S1].
• The company ceased operations of Xinjiang Pharmaceutical on June 30, 2025 [S1].
• The company has engaged in patient-aid projects, establishing online columns for cancer-related and rare disease drug treatments, facilitating free drug access for qualified patients and charging customers for related services [S1].
• Zhongchao Inc. completed a 1-for-10 share consolidation in February 2024 and a 1-for-8 share consolidation in March 2026, affecting share capital and voting rights [S1].
• As of December 31, 2025, the company reported cash and equivalents of $8.1 million, short-term investments of $5.8 million, current assets of $16.9 million, and current liabilities of $1.5 million, resulting in a current ratio of 11.11 and a cash ratio of 9.12, indicating strong liquidity [S1].
• For the fiscal year ended December 31, 2025, Zhongchao reported revenues of approximately $11.4 million and a net loss of about $6.3 million, with basic and diluted EPS of -$1.85 [S1].
• In March 2026, three officers resigned due to business strategy adjustments; the resignations were not due to disagreements with the company [S2].
• The company’s Class B ordinary shares have enhanced voting rights, with each Class B share entitled to 1,000 votes as of February 2026, while Class A shares have one vote each [S1].
• The company’s business model focuses on online and onsite healthcare education, professional training, and patient management services, with plans to expand medical specialty areas and improve course quality through cooperation with medical associations and international providers [S1].
• Recent news highlights include mixed financial results for 2024 and clinical momentum updates, with some investor concerns about returns on capital [N2][N1][N3].